摘要
目的 探讨碱性磷酸酶(alkaline phosphatase, ALP)和血清铁蛋白(serum ferritin, SF)对肾透明细胞癌与肾良性病变的早期鉴别和预后评估的临床意义。方法 收集2022年4月至2023年4月在解放军总医院第一医学中心手术治疗的肾透明细胞癌患者224例、肾良性病变患者45例的临床资料,对患者基本信息,病理报告及血清相关指标进行统计分析。结果 分析显示肾透明细胞癌患者的性别、ALP、γ-谷氨酰转移酶(γ-GGT)和SF水平显著高于肾良性病变组(P<0.05);按肾透明细胞癌WHO/ISUP核分级分成4组,SF随着分级严重程度的增加而逐步升高,并差异具有统计学意义(P<0.05)。而按照免疫组化指标细胞增殖核抗原Ki67(Ki67)阳性百分比分为两组,其中ki67≥20%组的ALP、SF明显高于ki67<20%组(P<0.05)。结论 ALP和SF对肾透明细胞癌的鉴别诊断具有一定的参考价值。
Objective To investigate the clinical significance of alkaline phosphatase(ALP)and serum ferritin(SF)in the early identification and prognosis evaluation of clear cell renal cell carcinoma and renal benign lesions.Methods The clinical data of 224 patients with clear cell renal cell carcinoma and 45 patients with benign renal lesions who underwent surgical treatment in the First Medical Center of Chinese PLA General Hospital from April,2022 to April,2023 were collected for the current study.The basic clinical information,pathological reports and serum related indicators of the patients were obtained and statistically analyzed.Results The analysis showed that the gender,ALP,γ-glutamyl transferase(γ-GGT)and SF levels in patients with clear cell renal cell carcinoma were significantly higher than those with benign renal lesions(P<0.05).According to WHO/ISUP nuclear classification of renal clear cell carcinoma,patients were divided into 4 groups.SF gradually increased with the increase of grading severity,and was statistically significant(P<0.05).According to the immunohistochemical index of cell proliferation nuclear antigen Ki67(Ki67)positive percentage was divided into two groups,in which ALP and SF in ki67≥20%group were significantly higher than that of ki67<20%group(P<0.05).Conclusion ALP and SF have certain reference value for the differential diagnosis of clear cell renal cell carcinoma.
作者
徐文婕
冯杰
王山
高艳红
XU Wenjie;FENG Jie;WANG Shan;GAO Yanhong(Department of Laboratory,the First Medical Center,Chinese PLA General Hospital,Beijing,China 100853;Department of Laboratory,West District,Hefei First People’s Hospital,Hefei 230031,China;Clinical Biobank Center,Medical Innovation Research Division,Chinese PLA General Hospital,Beijing 100853,China)
出处
《标记免疫分析与临床》
CAS
2023年第10期1627-1631,共5页
Labeled Immunoassays and Clinical Medicine
基金
国家重点研发计划(编号:2021YFC2009300,2021YFC2009301)。
关键词
肾透明细胞癌
肾良性病变
术前
碱性磷酸酶
血清铁蛋白
Clear cell renal cell carcinoma
Benign renal lesions
Preoperative
Alkaline phosphatase
Serum ferritin
